Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Magenta Therapeutics, Inc. (MGTA)

0.6996   -0.059 (-7.74%) 09-11 16:00
Open: 0.7085 Pre. Close: 0.7583
High: 0.7589 Low: 0.69
Volume: 375,912 Market Cap: 42(M)

Technical analysis

as of: 2023-09-27 10:18:00 AM
Short-term rate:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Mid-term rate:       
Target: Six months: 0.9     One year: 0.96
Support: Support1: 0.68    Support2: 0.57
Resistance: Resistance1: 0.77    Resistance2: 0.82
Pivot: 0.75
Moving Average: MA(5): 0.74     MA(20): 0.76
MA(100): 0.73     MA(250): 0.86
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 39.7     %D(3): 51.6
RSI: RSI(14): 36.8
52-week: High: 2.06  Low: 0.32
Average Vol(K): 3-Month: 267 (K)  10-Days: 210 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ MGTA ] has closed below the lower bollinger band by 19.5%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 30.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.78 - 0.78 0.78 - 0.79
Low: 0.72 - 0.72 0.72 - 0.72
Close: 0.75 - 0.76 0.76 - 0.77

Company Description

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Headline News

Tue, 19 Sep 2023
Metachromatic Leukodystrophy Market to Observe Impressive Growth During the Forecast Period (2023-2032), - Benzinga

Mon, 11 Sep 2023
Why Avantax Shares Are Trading Higher By Over 27%? Here Are ... - UK

Mon, 11 Sep 2023
Magenta Therapeutics Announces Completion of Merger with ... - GlobeNewswire

Thu, 31 Aug 2023
North American Morning Briefing : PCE Inflation -2- - 2023-08-31 -

Thu, 11 May 2023
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors ... - GlobeNewswire

Wed, 03 May 2023
Magenta Therapeutics and Dianthus Therapeutics Announce ... - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 61 (M)
Shares Float 34 (M)
% Held by Insiders 2.2 (%)
% Held by Institutions 62.6 (%)
Shares Short 383 (K)
Shares Short P.Month 393 (K)

Stock Financials

EPS -1.15
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.24
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -28.9
Return on Equity (ttm) -65.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.95
Qtrly Earnings Growth 0
Operating Cash Flow -73 (M)
Levered Free Cash Flow -30 (M)

Stock Valuations

PE Ratio -0.61
PEG Ratio 0
Price to Book value 0.56
Price to Sales 0
Price to Cash Flow -0.59

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.